[⁶⁸Ga]Ga-CTR-FAPI与[⁶⁸Ga]Ga-FAPI-04 PET/CT在碘难治性分化型甲状腺癌患者评估中的前瞻性对比研究
该单中心前瞻性研究纳入40例碘难治性分化型甲状腺癌(RAIR-DTC)远处转移患者,序贯行[⁶⁸Ga]Ga-FAPI-04与[⁶⁸Ga]Ga-CTR-FAPI PET/CT。结果显示[⁶⁸Ga]Ga-CTR-FAPI在病灶检出率(99.2% vs. 62.4%)、摄取值及靶本比方面均优于[⁶⁸Ga]Ga-FAPI-04,尤其在肺、胸腹膜、淋巴结和骨转移中优势显著。
要点
- [⁶⁸Ga]Ga-CTR-FAPI PET/CT病灶总检出率99.2%(763/769),显著高于[⁶⁸Ga]Ga-FAPI-04的62.4%(480/769)。
- 肺转移检出率99.4% vs. 37.5%,胸腹膜99.0% vs. 76.4%,淋巴结99.0% vs. 81.7%,骨100% vs. 82.9%。
- 17.5%(7/40)患者中[⁶⁸Ga]Ga-CTR-FAPI视觉检出分布区域更优(p=0.016)。
核心结论
- [⁶⁸Ga]Ga-CTR-FAPI PET/CT在RAIR-DTC患者中病灶检出率更高、示踪剂摄取更高、靶本对比更好,有助于更全面评估肿瘤负荷。
研究设计与样本
- 单中心前瞻性对比研究,纳入40例RAIR-DTC远处转移患者,间隔24-48小时序贯行[⁶⁸Ga]Ga-FAPI-04与[⁶⁸Ga]Ga-CTR-FAPI PET/CT,两名核医学医师盲法视觉分析,半定量测量SUVmax和TBR。
主要发现
- 40例中37例两种显像均检出转移灶,2例仅[⁶⁸Ga]Ga-CTR-FAPI检出病灶。
- 共确认769个转移灶,[⁶⁸Ga]Ga-CTR-FAPI检出99.2%(763/769),[⁶⁸Ga]Ga-FAPI-04检出62.4%(480/769),p<0.001。
- [⁶⁸Ga]Ga-CTR-FAPI在肺(99.4% vs. 37.5%)、胸腹膜(99.0% vs. 76.4%)、淋巴结(99.0% vs. 81.7%)和骨(100% vs. 82.9%)转移中检出率显著提高。
- 半定量分析显示[⁶⁸Ga]Ga-CTR-FAPI在肺转移(中位SUVmax 5.1 vs. 3.8)和骨转移(中位SUVmax 8.3 vs. 3.4)中摄取值更高,局部复发(中位TBR 11.2 vs. 8.6)和淋巴结转移(中位TBR 6.0 vs. 5.1)靶本比更高。
- [⁶⁸Ga]Ga-CTR-FAPI还检出额外的脑和肝转移灶,并在脑(n=1)、肝(n=2)、肾(n=1)共享病灶中摄取值更高;唯一纵隔软组织转移灶[⁶⁸Ga]Ga-FAPI-04的SUVmax略高。
关键数值与推荐
- 视觉分析由两名有经验的核医学医师盲法进行,病灶确认参考标准为常规影像、组织病理学结果(可行时)及长期临床-影像随访的综合。
临床怎么用
- [⁶⁸Ga]Ga-CTR-FAPI PET/CT可提高RAIR-DTC患者转移灶检出率,尤其对肺、胸腹膜、淋巴结和骨转移,有助于更全面评估肿瘤负荷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Incorporating a sulfur (VI)-fluoride exchange (SuFEx) chemistry-based linker, FAPI-based covalent targeted radioligand (CTR) showed better tumor binding affinity and longer retention time than FAPI-04 in animal studies. This study for the first time compared the lesion detection efficacy of [⁶⁸Ga]Ga-CTR-FAPI PET/CT and [⁶⁸Ga]Ga-FAPI-04 PET/CT in a radioiodine-refractory differentiated thyroid cancer clinical cohort. METHODS: A single-center prospective comparative study was conducted, enrolling 40 RAIR-DTC patients with distant metastases. All patients underwent sequential [⁶⁸Ga]Ga-FAPI-04 PET/CT and [⁶⁸Ga]Ga-CTR-FAPI PET/CT examinations at a 24-48 h interval. Two experienced nuclear medicine physicians performed blinded visual analysis of the images to assess lesion detection status. Semi-quantitative analysis included the measurement of maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) of lesions in different anatomical regions. The reference standard for lesion confirmation was a combination of conventional imaging, histopathological results (when feasible), and long-term clinico-radiological follow-up. The detection performances of the two imaging modalities were compared at the patient and lesion levels. RESULTS: Of the 40 enrolled patients, 37 had detectable metastatic lesions on both imaging modalities. Two patients had lesions exclusively detected by [⁶⁸Ga]Ga-CTR-FAPI PET/CT. [⁶⁸Ga]Ga-CTR-FAPI PET/CT achieved superior visual detection performance in 17.5% (7/40) of patients (p = 0.016) concerning lesion distribution areas. In total, 769 metastatic lesions were identified by the two tracers, with [⁶⁸Ga]Ga-CTR-FAPI PET/CT detecting 99.2% (763/769) and [⁶⁸Ga]Ga-FAPI-04 PET/CT detecting 62.4% (480/769) of lesions (p < 0.001). [⁶⁸Ga]Ga-CTR-FAPI PET/CT significantly improved detection rates in lung (99.4% vs. 37.5%, p < 0.001), pleural/peritoneal (99.0% vs. 76.4%, p < 0.001), lymph node (99.0% vs. 81.7%, p < 0.001) and bone (100% vs. 82.9%, p = 0.031) metastases. Semi-quantitative analysis showed that [⁶⁸Ga]Ga-CTR-FAPI PET/CT had significantly higher median SUVmax in lung (5.1 vs. 3.8, p < 0.001) and bone (8.3 vs. 3.4, p = 0.013) metastases, and significantly higher median TBR in local recurrence (11.2 vs. 8.6, p = 0.045) and lymph node metastases (6.0 vs. 5.1, p = 0.026) compared with [⁶⁸Ga]Ga-FAPI-04 PET/CT. Furthermore, [⁶⁸Ga]Ga-CTR-FAPI PET/CT exhibited additional cerebral and hepatic metastatic lesions as well as higher tracer uptake in shared lesions located at brain (n = 1), liver(n = 2) and kidney (n = 1), while the only mediastinal soft tissue metastasis showed an SUVmax slightly higher in [⁶⁸Ga]Ga-FAPI-04 PET/CT. CONCLUSION: [⁶⁸Ga]Ga-CTR-FAPI PET/CT exhibits superior lesion detection rate, higher tracer uptake and better tumor-to-background contrast compared with [⁶⁸Ga]Ga-FAPI-04 PET/CT in RAIR-DTC patients, thus enhances the comprehensive assessment of patients' tumor burden. These findings stimulate further research on the application of CTR-FAPI as a novel and promising theranostic agent. TRIAL REGISTRATION: ChiCTR ChiCTR2400091757. Registered 2 November 2024.
引用
- Liu S, Zhang X, Li R, et al. [⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42700251. doi:10.1007/s00259-026-08150-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。